Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.
Hi Violindog
I think that the fact that three new industry investors have just climbed aboard tells us that Scancell are becoming a prime target.
The next set of results will place Immunobody and Moditope at the top of many Large Pharma lists of possible acquisitions.
Chester.
There is a good probability that we will hear how the trial for Modi1 + CPi ( Anti PD1 only ) in Renal & Head and Neck cancers is proceeding.
31st July that Cohort was approved and the aim was to enrol 21 patients in each setting.
By the Interim Report there will have been a time period of some 25 weeks to Enrol, have 1st dose and reach 1st scan for a number of patients. Based on previous updates we should be given an overview for part of those cohorts.
In the Neoadjuvant Cohort the 1st patient was not dosed until 30th November ( confirmed at the AGM ).
The procedure was to take a biopsy then 2 x doses of Modi1 3 weeks apart and then resection of the tumour 6 weeks later. The very 1st patient will not reach the resection stage until the end of this month at the earliest.
So on Modi1 + CPI, I would expect details on the numbers of enrolled patients and some information about the resulting 1st scans of those reaching that point. Similar to last years update RNS.
Chester.
Having been invested in Scancell for a decade, I am also frustrated by the current shareprice as it feels like it should be much higher. Part of that is solely due to the fact that we have been above 20p several times and seemed to be one piece of good news from heading higher. I don't think being on the AIM market helps either.
What we do know is that Scancell's platforms have the potential to be worth many multiples of 11p.
Chester.
What can we expect from the Half Yearly Update, due at the end of this month ?
Last year we were told how the trials were progressing and the numbers of enrolled patients. Should we expect a detailed update on both SCOPE and ModiFY ?
Chester.
Scancell's share price is currently floating around 11p even though we have two incredible trials running, 61 highly capable staff and roughly £15m in cash.
Back when we had 230m shares in issue and only the promise of what Immunobody or Moditope could achieve the share price was circa 5p.
I remember thinking what a steal 5p was set against the potential waiting to be unlocked.
I'm back to thinking the same now about 11p.
Based only on the data released so far from the SCOPE trial and the confidence shown by LD in the potential of iSCIB+. Added to that, If Modi1 + CPI'S has anything like the same impact on positive treatment outcomes 11p becomes a serious joke.
When we reach the end of this year I honestly think we will look back at this current 11p as a gift for those that took advantage.
To all Scancell shareholders I say, 'stay patience and keep the faith' 2024 is already loaded up with the potential of many inflection points.
Chester.
Happy New Year All.
Did someone recently post that the JP Mogan event is by invitation only ?
If that's the case, Sath going is really good news for Scancell. Shows there is real interest in the clinical trial results so far.
Chester.
The Circular is on Scancells website.
Under INVESTOR, find 2023 Capital Raise.
Click on 'I am located elsewhere'. Find and Click on 'Agree' which is at the bottom of the page.
Now choose, Scancell Circular November 2023.
That is the whole document which you will need to sift through. The important note is that the offer must be applied for by tomorrow 5th December.
Hope that helps.
Chester.
Our Chairman knows what he is doing. He identified very early on that the Science at Scancell had multiple potential directions.
You can guess that it was his view that the cash in the bank could only last if the science was reigned in.
Subsequently the decision was made to concentrate on the two Trials. Such things as Modi2 and pursuing an in-house trial on one of our GlyMabs would have to wait for the company to reach cash independence.
This capital raise is doubling down on being totally secure to reach pivitol data points in, I presume, both trials.
There is a possibility that the early trial data ( 2024 ) will be outstanding and a predatory Pharma might make thier move.
Alternatively, we don't know what 2024 will bring, climate, economics, wars and the US election. So ensuring Scancell is well and truly funded is the most pragmatic thing he could do.
So to reach £1 / share, instead of asking for £1B when the data lands early 2025 they now need ask for £1.2B.
Simples.......
Chester.
There were quite a few hints right at the beginning of Botski's recording.
REDMILE, happy with their 29.4% of the company and do not want to take control.
ie: not putting any more funds into Scancell.
GENMAB: Early Milestones not a large amount and all the large cash arrives when they reach phase 3 trials. In around 5 years.
BIG PHARMA: Want a de-risked platform then happy to pay more.
ADDED TOGETHER :
Get the SCOPE trial to the edge of registration and we'll buy the blooming lot.
So this raise is absolutely positive if you believe Immunobody and Moditope work ( the trials say they do ) get your cash out and join in the raise. An over subscribed cash raise tells the wider market to get on board.
Chester.
Hi C11
From what we have been told, the clinical scans that are necessary to build up the data happen at 13 weeks. Noting that the enrolment of the extra 27 patients to the SCOPE trial could have started as early as late September, I'm hopeful that Scancell will hit the required number of responders by February/March.
The Modi1 plus CPi cohort should also reached an important data point around the same time.
As you say, the disclosing RNS'es could land early part of April ( Q2 ). Let's hope that great data arrives on both Trials by then.
Chester.
Thanks Botski really appreciated the chance to listen to whole AGM. Sadly I had to abandon my journey to London at the last minute.
One thing I picked up on, was our Chairman more or less saying that the difficulty with Scancell is the 'Abundance of Richies'.
Since arriving he has brought clarity in the relationship of the platforms / cash needed to achieve important revenue goals. Not trying to cover all bases at once.
Both SCOPE and ModiFY are well poised to produce very valuable data early in 2024.
Chester.
WTP just to add spice to my last post,
"The Successful Transition into the Second Stage" was stated in the RNS dated 19th September.
Two months ago, so we can presume the first of those patients are already recruited and 1st dosed.
We could be well into that number of 27 patients, very exciting times. ( Modi1 + CPI's Next ).
Chester.
WeTookPelham
Let's wait and see how the AGM unfolds.
It's getting awful close to a point where Bristol Myers Squibb are compelled to make Scancell an Offer or broker a deal for a Worldwide Development and Distribution Partnership.
Once this has been achieved :
" The SCOPE trial has now successfully transitioned into the second stage, which will recruit a further 27 patients (for a total of 43). The aim is to achieve at least 18 further responses (i.e., 27 responses in total) which would statistically demonstrate that SCIB1, in combination with doublet therapy, exceeds currently achievable ORRs".
LD will be fending of any Derisory Offers.
Chester.
C11
I totally agree but also want MHRA to only proceed when they are convinced the additional epitopes and the inclusion of AvidiMab are safe.
ISCIB+ is oncology technology that is so new that safety 'belts and braces' are necessary.
As already mentioned, once approval is given it will not take long to enroll the required number of patients. The current Scope Trail is restricted to around 30% of Melanoma suffers. The news of how well SCIB1 + the CPI'S is doing will be known to all the cancer clinicians involved in oncology / Immunology.
If we were ever concerned that we hadn't backed a winner in Scancell, well now we know we have. It's just a matter of time and the positive data will arrived.
Chester.
A genuinely fantastic RNS, not only the increase to 85% but a patient with a clear scan.
In a late stage aggressive desiese these are outstanding outcomes.
If Modi1 plus CPI's match these results there will surely be a bid for the company. There are a half dozen or more Large Pharma Co's that would love to these platforms in-house.
Excellent news for us and cancer patients.
Chester.
From the Reneuron RNS 8th November,
'The Group ended the period to 30 September 2023 with cash, cash equivalents and bank deposits of £5.1 million with the cash runway being extended into the start of calendar Q2 2024.'
No mention of Q125.
Year dates all wrong.
"As of 30 September 2023, Reneuron had cash balance of £5.1m, which we estimate should fund operations into 'Q125', consistent with management's expected cash runway to April 2024" ????
More errors in the Full Report.
Technology making the world dumber.
Only things that have been RNS'd to the market can be discussed at the AGM. What can be projected either via the presentation or the Q&A section, is how things are progressing especially the Trials and potential discussions becoming Deals.
There is time yet to have an RNS land.
For instance, it would be nice to hear if iSCIB+ is close to approval.
Chester.